JP2017527567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527567A5 JP2017527567A5 JP2017512976A JP2017512976A JP2017527567A5 JP 2017527567 A5 JP2017527567 A5 JP 2017527567A5 JP 2017512976 A JP2017512976 A JP 2017512976A JP 2017512976 A JP2017512976 A JP 2017512976A JP 2017527567 A5 JP2017527567 A5 JP 2017527567A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- preparation
- formula
- compound
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 9
- 239000003153 chemical reaction reagent Substances 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 229960004106 citric acid Drugs 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 230000008707 rearrangement Effects 0.000 claims 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 3
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 230000008030 elimination Effects 0.000 claims 2
- 238000003379 elimination reaction Methods 0.000 claims 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- FMGZEUWROYGLAY-UHFFFAOYSA-N Halosulfuron-methyl Chemical compound ClC1=NN(C)C(S(=O)(=O)NC(=O)NC=2N=C(OC)C=C(OC)N=2)=C1C(=O)OC FMGZEUWROYGLAY-UHFFFAOYSA-N 0.000 claims 1
- 102100039489 Histone-lysine N-methyltransferase, H3 lysine-79 specific Human genes 0.000 claims 1
- 101000963360 Homo sapiens Histone-lysine N-methyltransferase, H3 lysine-79 specific Proteins 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 229960004543 anhydrous citric acid Drugs 0.000 claims 1
- 230000001754 anti-pyretic effect Effects 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 1
- 229960002303 citric acid monohydrate Drugs 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000011132 hemopoiesis Effects 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 230000011987 methylation Effects 0.000 claims 1
- 238000007069 methylation reaction Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051904P | 2014-09-17 | 2014-09-17 | |
| US62/051,904 | 2014-09-17 | ||
| PCT/US2015/050785 WO2016044649A1 (en) | 2014-09-17 | 2015-09-17 | Injectable formulations for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017527567A JP2017527567A (ja) | 2017-09-21 |
| JP2017527567A5 true JP2017527567A5 (enExample) | 2018-10-25 |
Family
ID=55533871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512976A Pending JP2017527567A (ja) | 2014-09-17 | 2015-09-17 | 癌の治療のための注射製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20170290765A1 (enExample) |
| EP (1) | EP3193879A4 (enExample) |
| JP (1) | JP2017527567A (enExample) |
| AU (1) | AU2015317509A1 (enExample) |
| CA (1) | CA2960287A1 (enExample) |
| WO (1) | WO2016044649A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014039839A1 (en) | 2012-09-06 | 2014-03-13 | Epizyme, Inc. | Method of treating leukemia |
| EP2968387A4 (en) | 2013-03-15 | 2017-04-05 | Epizyme, Inc. | Methods of synthesizing substituted purine compounds |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2149150C (en) * | 1992-11-27 | 2000-08-01 | David R. Carver | Injectable taxol composition with improved stability |
| JP2003321364A (ja) * | 2002-05-07 | 2003-11-11 | Eisai Co Ltd | シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物 |
| JP2006199588A (ja) * | 2003-05-06 | 2006-08-03 | Senju Pharmaceut Co Ltd | オキサゾリジノン誘導体含有水性液剤 |
| US20060128653A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
| WO2008088816A1 (en) * | 2007-01-18 | 2008-07-24 | Pgxhealth, Llc | Adenosine derivative formulations for medical imaging |
| RU2470636C2 (ru) * | 2007-04-27 | 2012-12-27 | Сайдекс Фамэсьютиклз, Инк. | Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты) |
| EP2629775A4 (en) * | 2010-10-18 | 2014-06-11 | Dainippon Sumitomo Pharma Co | INJECTABLE FORMULATION WITH DELAYED RELEASE |
| BR112013013659B8 (pt) * | 2010-12-03 | 2024-02-27 | Epizyme Inc | Compostos moduladores de enzimas epigenéticas, composição farmacêutica compreendendo ditos compostos e usos da dita composição farmacêutica para tratar câncer, câncer hematológico ou leucemia |
| GB201021267D0 (en) * | 2010-12-15 | 2011-01-26 | Reckitt Benckiser Healthcare Int Ltd | Novel pharmaceutical formulation |
| US20150284422A1 (en) * | 2012-08-10 | 2015-10-08 | Epizyme, Inc. | Inhibitors of protein methyltransferase dot1l and methods of use thereof |
| WO2014039839A1 (en) * | 2012-09-06 | 2014-03-13 | Epizyme, Inc. | Method of treating leukemia |
| CA2894220A1 (en) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Dot1l inhibitors for use in the treatment of leukemia |
| JP2016513699A (ja) * | 2013-03-15 | 2016-05-16 | エピザイム,インコーポレイティド | 癌の治療のための注射製剤 |
-
2015
- 2015-09-17 EP EP15841842.6A patent/EP3193879A4/en not_active Withdrawn
- 2015-09-17 US US15/512,528 patent/US20170290765A1/en not_active Abandoned
- 2015-09-17 WO PCT/US2015/050785 patent/WO2016044649A1/en not_active Ceased
- 2015-09-17 AU AU2015317509A patent/AU2015317509A1/en not_active Abandoned
- 2015-09-17 CA CA2960287A patent/CA2960287A1/en not_active Abandoned
- 2015-09-17 JP JP2017512976A patent/JP2017527567A/ja active Pending
-
2019
- 2019-06-06 US US16/433,259 patent/US20190388335A1/en not_active Abandoned
-
2020
- 2020-12-22 US US17/130,936 patent/US20210251887A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013377736B2 (en) | Oral antiseptic composition for treating oral mucositis | |
| JP2011102304A5 (enExample) | ||
| JP2016515628A5 (enExample) | ||
| CN105555276A (zh) | 作为治疗病毒性感染的药剂的贝前列素异构体 | |
| JP2012521435A5 (enExample) | ||
| JP2018513188A5 (enExample) | ||
| CA3019769C (en) | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2011503044A5 (enExample) | ||
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| JP2019518798A (ja) | リポヌクレオチドに基づくardsの治療 | |
| JP2015517523A5 (enExample) | ||
| JP2017527567A5 (enExample) | ||
| JP2016512818A5 (enExample) | ||
| RU2015119377A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
| JP2014148552A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JP2008533135A (ja) | ゲムシタビン誘導体の経口投薬形態 | |
| JP2020510043A5 (enExample) | ||
| HRP20210418T1 (hr) | Liječenje s syd985 pacijenata s rakom koji ne reagira na t-dm1 | |
| CN109758452A (zh) | 胺类化合物治疗疼痛的医药用途 | |
| CN104968340A (zh) | 治疗肝脏疾病或病状的用途和方法 | |
| JP2023511319A (ja) | がんを調節するための組成物および方法 | |
| CN110638802A (zh) | Atca在制备治疗肿瘤的药物中的用途 | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. |